Life Sciences

AI reshapes biopharma from gene to patient

The Economic Times reported expanding AI use in genetic interpretation, risk prediction, and cell- and gene-therapy design, citing more than 173 AI-originated clinical programs.

An article from The Economic Times described the growing use of AI across biopharmaceutical development, including genetic-variant interpretation, polygenic-risk scoring, and the design of cell and gene therapies. The report stated that more than 173 AI-originated programs were in clinical development and that analysts put the probability of a first FDA approval by 2027 at 60 percent. These figures indicate increasing investment in AI-generated therapeutic candidates and computational biology. The available search result does not provide enough detail to independently verify the program count, identify the underlying datasets, or evaluate the analysts’ methodology.

Original source: The Economic Times

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI